Skip to main content

2020 - RAS Dialogue

    • SOS signaling in RAS-mutated cancers
      , by Erin Sheffels and Rob Kortum

      SOS proteins participate in controlling the activity of the RAS pathway, even when RAS itself is mutated and driving cancer. Inhibitors of SOS in combination with other drugs show promise as elements of new cancer therapies.

      Continue Reading >

    • RAS Mutation Tropism
      , by Siqi Li, David MacAlpine, and Christopher M Counter

      The three isoforms of Ras share signaling modalities, yet their cancer-associated mutations vary widely in sequence and the organs affected. Sequencing those mutations very soon after they occur sheds light on the forces driving those differences.

      Continue Reading >

    • The disease burden of Ras
      , by Ian A Prior

      Cancer genome databases yield different estimates of the importance of RAS genes in cancers. Integrating the data that underlie those estimates may suggest new research priorities based on patient numbers.

      Continue Reading >

    • Alternative cells-of-origin influence the heterogeneity of KRAS-mutant lung adenocarcinoma
      , by Sarah Best and Kate Sutherland

      The biology of lung cancers driven by mutant KRAS is substantially influenced by the particular cell type in which the KRAS mutation arose. Understanding how the cell of origin and its surroundings react to mutant KRAS suggest therapeutic approaches.

      Continue Reading >

    • The RASopathies Network
      , by Lisa Schoyer and Beth Stronach

      RASopathies are neurodevelopmental genetic syndromes caused by germline mutations in RAS pathway genes that result in increased MAPK signaling. The RASopathies Network provides an umbrella organization to connect affected families with researchers.

      Continue Reading >